Work

Abstract CT125: A Phase 1 study to evaluate the safety and tolerability of a combination autologous CD19 CAR T cell therapy (SYNCAR-001) and orthogonal IL-2 (STK-009) in subjects with relapsed or refractory CD19 expressing hematologic malignancies (NCT05665062)

Year: 2023

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.am2023-ct125

Authors: Maria Lia Palomba, Matthew G. Mei, Paolo F. Caimi, Matthew Cortese, Marco Davila, Greg Yadnik, Nestor Huang, David Mou, Martin Oft, Paul-Joseph Aspuria, Anita Mehta-Damani, Navneet Ratti, Naiyer Rizvi, Alex Azrilevich, Ran Reshef

Institutions: Memorial Sloan Kettering Cancer Center, City Of Hope National Medical Center, Cleveland Clinic, Roswell Park Comprehensive Cancer Center, Synthekine, Columbia University Irving Medical Center

Language: English

Topic: CAR-T cell therapy research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4365512303

Cites:

Cited by: 3

Related to: 10